Pfizer doles out $2.3B for blood cancer player to flesh out its end-of-decade oncology portfolio

Kyle Blankenship

As its Covid-19 vaccine rakes in cash, Pfizer is in a position to move boldly as it looks at the hazy end of the current decade. Seeking peace of mind, the drugmaker has signed a rich deal with a familiar CD47 player to help firm up its next-gen game plans.

Pfizer will pay $2.26 billion to acquire Canadian biotech Trillium Therapeutics and its lead molecules targeting the signal regulatory protein-α (SIRPα)–CD47 axis for blood cancers as part of a push to add firepower to the Big Pharma’s oncology portfolio for the late 2020s, the partners said in a release Monday.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

Pfizer doles out $2.3B for blood cancer player to flesh out its end-of-decade oncology portfolio

Kyle Blankenship

Unlock this article instantly by becoming a free subscriber.

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

Rare neuro disorder offers new area for competition, analysts say: #AAN24

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Senators want to know more on why Novo is discontinuing its insulin Levemir

Pfiz­er doles out $2.3B for blood can­cer play­er to flesh out its end-of-decade on­col­o­gy port­fo­lio

Kyle Blankenship

Unlock this article instantly by becoming a free subscriber.

more like this

J&J's AI head jumps to Re­cur­sion; Doug Williams re­signs as Sana's R&D chief

Ver­tex, Alpine’s IgAN drug has Hu­mi­ra-like po­ten­tial. But not all in­di­ca­tions are cre­at­ed equal

Rare neu­ro dis­or­der of­fers new area for com­pe­ti­tion, an­a­lysts say: #AAN24

CSL Vi­for pro­pos­es a mar­ket­ing cam­paign to set­tle Eu­ro­pean Com­mis­sion in­ves­ti­ga­tion

Take­da wins la­bel ex­pan­sion for sub­cu­ta­neous En­tyvio, cre­at­ing 'flex­i­bil­i­ty' for Crohn's pa­tients

Sen­a­tors want to know more on why No­vo is dis­con­tin­u­ing its in­sulin Lev­emir

Pfizer doles out $2.3B for blood cancer player to flesh out its end-of-decade oncology portfolio

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

Rare neuro disorder offers new area for competition, analysts say: #AAN24

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Senators want to know more on why Novo is discontinuing its insulin Levemir